▶ 調査レポート

転移性黒色腫治療薬の世界市場レポート2020

• 英文タイトル:Global Metastatic Melanoma Drug Sales Market Report 2020

QYResearchが調査・発行した産業分析レポートです。転移性黒色腫治療薬の世界市場レポート2020 / Global Metastatic Melanoma Drug Sales Market Report 2020 / 20QY06-07515資料のイメージです。• レポートコード:20QY06-07515
• 出版社/出版日:QYResearch / 2020年6月1日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、148ページ
• 納品方法:Eメール(受注後2~3営業日)
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥592,000 (USD4,000)▷ お問い合わせ
  Multi User¥888,000 (USD6,000)▷ お問い合わせ
  Enterprise License¥1,184,000 (USD8,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社の当調査資料では、転移性黒色腫治療薬のグローバル市場について種類別(AGI-134、ALT-801、ALT-803、AMG-232、その他)、用途別(病院、クリニック、その他)、地域別(北米、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。

・転移性黒色腫治療薬市場の概要
・世界の主要地域別転移性黒色腫治療薬市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界の転移性黒色腫治療薬市場規模2015-2026:種類別(AGI-134、ALT-801、ALT-803、AMG-232、その他)
・世界の転移性黒色腫治療薬市場規模2015-2026:用途別(病院、クリニック、その他)
・転移性黒色腫治療薬の北米市場規模2015-2020
・転移性黒色腫治療薬のヨーロッパ市場規模2015-2020
・転移性黒色腫治療薬の中国市場規模2015-2020
・転移性黒色腫治療薬の日本市場規模2015-2020
・転移性黒色腫治療薬の東南アジア市場規模2015-2020
・転移性黒色腫治療薬のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
(Merck & Co., Inc.、Merck KGaA、Millennium Pharmaceuticals, Inc.、Morphotek, Inc.、NewLink Genetics Corporation、Novartis AG、Omeros Corporation、Oncolytics Biotech Inc.、OncoSec Medical Inc.、Ono Pharmaceutical Co., Ltd.、Pfizer Inc.、Pharmis Biofarmaceutica, Lda.、Philogen S.p.A.、Plexxikon Inc.)
・転移性黒色腫治療薬の製造コスト分析
・販売チャネル、流通業者、顧客
・転移性黒色腫治療薬の市場動向・機会・課題
・調査の結論

Market Analysis and Insights: Global Metastatic Melanoma Drug Market
The global Metastatic Melanoma Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Metastatic Melanoma Drug Scope and Market Size
The global Metastatic Melanoma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Melanoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Metastatic Melanoma Drug market is segmented into
AGI-134
ALT-801
ALT-803
AMG-232
Others

Segment by Application, the Metastatic Melanoma Drug market is segmented into
Hospital
Clinic
Others
The Metastatic Melanoma Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Metastatic Melanoma Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Metastatic Melanoma Drug Market Share Analysis
Metastatic Melanoma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Metastatic Melanoma Drug business, the date to enter into the Metastatic Melanoma Drug market, Metastatic Melanoma Drug product introduction, recent developments, etc.
The major vendors covered:
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.

レポート目次

Table of Contents

1 Metastatic Melanoma Drug Market Overview
1.1 Metastatic Melanoma Drug Product Scope
1.2 Metastatic Melanoma Drug Segment by Type
1.2.1 Global Metastatic Melanoma Drug Sales by Type (2020-2026)
1.2.2 AGI-134
1.2.3 ALT-801
1.2.4 ALT-803
1.2.5 AMG-232
1.2.6 Others
1.3 Metastatic Melanoma Drug Segment by Application
1.3.1 Global Metastatic Melanoma Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Metastatic Melanoma Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Metastatic Melanoma Drug Sales Growth Rate (2015-2026)
1.4.2 Global Metastatic Melanoma Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Metastatic Melanoma Drug Price Trends (2015-2026)

2 Metastatic Melanoma Drug Estimate and Forecast by Region
2.1 Global Metastatic Melanoma Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Metastatic Melanoma Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Metastatic Melanoma Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Metastatic Melanoma Drug Revenue Market Share by Region (2015-2020)
2.3 Global Metastatic Melanoma Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Metastatic Melanoma Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Metastatic Melanoma Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Metastatic Melanoma Drug Estimates and Projections (2015-2026)
2.4.2 Europe Metastatic Melanoma Drug Estimates and Projections (2015-2026)
2.4.3 China Metastatic Melanoma Drug Estimates and Projections (2015-2026)
2.4.4 Japan Metastatic Melanoma Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Metastatic Melanoma Drug Estimates and Projections (2015-2026)
2.4.6 India Metastatic Melanoma Drug Estimates and Projections (2015-2026)
3 Global Metastatic Melanoma Drug Competition Landscape by Players
3.1 Global Top Metastatic Melanoma Drug Players by Sales (2015-2020)
3.2 Global Top Metastatic Melanoma Drug Players by Revenue (2015-2020)
3.3 Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Melanoma Drug as of 2019)
3.4 Global Metastatic Melanoma Drug Average Price by Company (2015-2020)
3.5 Manufacturers Metastatic Melanoma Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Metastatic Melanoma Drug Players (Opinion Leaders)
4 Global Metastatic Melanoma Drug Market Size by Type
4.1 Global Metastatic Melanoma Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Metastatic Melanoma Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Metastatic Melanoma Drug Price by Type (2014-2020)
4.2 Global Metastatic Melanoma Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Metastatic Melanoma Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Metastatic Melanoma Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Metastatic Melanoma Drug Price Forecast by Type (2021-2026)
5 Global Metastatic Melanoma Drug Market Size by Application
5.1 Global Metastatic Melanoma Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Metastatic Melanoma Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Metastatic Melanoma Drug Price by Application (2015-2020)
5.2 Global Metastatic Melanoma Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Metastatic Melanoma Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Metastatic Melanoma Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Metastatic Melanoma Drug Price Forecast by Application (2021-2026)

3 North America Metastatic Melanoma Drug Market Facts & Figures
3.2 North America Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
3.3 North America Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
3.4 North America Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

4 Europe Metastatic Melanoma Drug Market Facts & Figures
4.2 Europe Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
4.3 Europe Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
4.4 Europe Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

5 China Metastatic Melanoma Drug Market Facts & Figures
5.2 China Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
5.3 China Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
5.4 China Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

6 Japan Metastatic Melanoma Drug Market Facts & Figures
6.2 Japan Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
6.3 Japan Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
6.4 Japan Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

7 Southeast Asia Metastatic Melanoma Drug Market Facts & Figures
7.2 Southeast Asia Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

8 India Metastatic Melanoma Drug Market Facts & Figures
8.2 India Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
8.3 India Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
8.4 India Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Metastatic Melanoma Drug Business
12.1 Merck & Co., Inc.
12.1.1 Merck & Co., Inc. Metastatic Melanoma Drug Corporation Information
12.1.2 Merck & Co., Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Products Offered
12.1.5 Merck & Co., Inc. Recent Development
12.2 Merck KGaA
12.2.1 Merck KGaA Metastatic Melanoma Drug Corporation Information
12.2.2 Merck KGaA Metastatic Melanoma Drug Business Overview and Total Revenue
12.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck KGaA Metastatic Melanoma Drug Products Offered
12.2.5 Merck KGaA Recent Development
12.3 Millennium Pharmaceuticals, Inc.
12.3.1 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Corporation Information
12.3.2 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Products Offered
12.3.5 Millennium Pharmaceuticals, Inc. Recent Development
12.4 Morphotek, Inc.
12.4.1 Morphotek, Inc. Metastatic Melanoma Drug Corporation Information
12.4.2 Morphotek, Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Morphotek, Inc. Metastatic Melanoma Drug Products Offered
12.4.5 Morphotek, Inc. Recent Development
12.5 NewLink Genetics Corporation
12.5.1 NewLink Genetics Corporation Metastatic Melanoma Drug Corporation Information
12.5.2 NewLink Genetics Corporation Metastatic Melanoma Drug Business Overview and Total Revenue
12.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Products Offered
12.5.5 NewLink Genetics Corporation Recent Development
12.6 Novartis AG
12.6.1 Novartis AG Metastatic Melanoma Drug Corporation Information
12.6.2 Novartis AG Metastatic Melanoma Drug Business Overview and Total Revenue
12.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Novartis AG Metastatic Melanoma Drug Products Offered
12.6.5 Novartis AG Recent Development
12.7 Omeros Corporation
12.7.1 Omeros Corporation Metastatic Melanoma Drug Corporation Information
12.7.2 Omeros Corporation Metastatic Melanoma Drug Business Overview and Total Revenue
12.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Omeros Corporation Metastatic Melanoma Drug Products Offered
12.7.5 Omeros Corporation Recent Development
12.8 Oncolytics Biotech Inc.
12.8.1 Oncolytics Biotech Inc. Metastatic Melanoma Drug Corporation Information
12.8.2 Oncolytics Biotech Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Products Offered
12.8.5 Oncolytics Biotech Inc. Recent Development
12.9 OncoSec Medical Inc.
12.9.1 OncoSec Medical Inc. Metastatic Melanoma Drug Corporation Information
12.9.2 OncoSec Medical Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Products Offered
12.9.5 OncoSec Medical Inc. Recent Development
12.10 Ono Pharmaceutical Co., Ltd.
12.10.1 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Corporation Information
12.10.2 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Business Overview and Total Revenue
12.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Products Offered
12.10.5 Ono Pharmaceutical Co., Ltd. Recent Development
12.11 Pfizer Inc.
12.11.1 Pfizer Inc. Metastatic Melanoma Drug Corporation Information
12.11.2 Pfizer Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Pfizer Inc. Metastatic Melanoma Drug Products Offered
12.11.5 Pfizer Inc. Recent Development
12.12 Pharmis Biofarmaceutica, Lda.
12.12.1 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Corporation Information
12.12.2 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Business Overview and Total Revenue
12.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Products Offered
12.12.5 Pharmis Biofarmaceutica, Lda. Recent Development
12.13 Philogen S.p.A.
12.13.1 Philogen S.p.A. Metastatic Melanoma Drug Corporation Information
12.13.2 Philogen S.p.A. Metastatic Melanoma Drug Business Overview and Total Revenue
12.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Philogen S.p.A. Metastatic Melanoma Drug Products Offered
12.13.5 Philogen S.p.A. Recent Development
12.14 Plexxikon Inc.
12.14.1 Plexxikon Inc. Metastatic Melanoma Drug Corporation Information
12.14.2 Plexxikon Inc. Metastatic Melanoma Drug Business Overview and Total Revenue
12.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Plexxikon Inc. Metastatic Melanoma Drug Products Offered
12.14.5 Plexxikon Inc. Recent Development

13 Metastatic Melanoma Drug Manufacturing Cost Analysis
13.1 Metastatic Melanoma Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Metastatic Melanoma Drug
13.4 Metastatic Melanoma Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Metastatic Melanoma Drug Distributors List
14.3 Metastatic Melanoma Drug Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables

Table 1. Global Metastatic Melanoma Drug Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Metastatic Melanoma Drug Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Metastatic Melanoma Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Metastatic Melanoma Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Metastatic Melanoma Drug Sales Market Share by Region (2015-2020)
Table 6. Global Metastatic Melanoma Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Metastatic Melanoma Drug Revenue Share by Region (2015-2020)
Table 8. Global Metastatic Melanoma Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Metastatic Melanoma Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Metastatic Melanoma Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Metastatic Melanoma Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Metastatic Melanoma Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Metastatic Melanoma Drug Sales Share by Company (2015-2020)
Table 14. Global Metastatic Melanoma Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Metastatic Melanoma Drug Revenue Share by Company (2015-2020)
Table 16. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Melanoma Drug as of 2019)
Table 17. Global Metastatic Melanoma Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Metastatic Melanoma Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Metastatic Melanoma Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Metastatic Melanoma Drug Players
Table 22. Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Metastatic Melanoma Drug Sales Share by Type (2015-2020)
Table 24. Global Metastatic Melanoma Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Metastatic Melanoma Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Metastatic Melanoma Drug Sales Share by Type (2021-2026)
Table 27. Global Metastatic Melanoma Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Metastatic Melanoma Drug Revenue Share by Type (2021-2026)
Table 29. Global Metastatic Melanoma Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Metastatic Melanoma Drug Sales Share by Application (2015-2020)
Table 32. Global Metastatic Melanoma Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Metastatic Melanoma Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Metastatic Melanoma Drug Sales Share by Application (2021-2026)
Table 36. Global Metastatic Melanoma Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Metastatic Melanoma Drug Revenue Share by Application (2021-2026)
Table 38. Global Metastatic Melanoma Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 41. United States Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 43. United States Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 51. China Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 53. China Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 55. China Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
Table 69. India Metastatic Melanoma Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Metastatic Melanoma Drug Sales Market Share by Company (2015-2020)
Table 71. India Metastatic Melanoma Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Metastatic Melanoma Drug Sales Market Share by Type (2015-2020)
Table 73. India Metastatic Melanoma Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Metastatic Melanoma Drug Sales Market Share by Application (2015-2020)
Table 75. Merck & Co., Inc. Corporation Information
Table 76. Merck & Co., Inc. Description and Business Overview
Table 77. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Merck & Co., Inc. Metastatic Melanoma Drug Product
Table 79. Merck & Co., Inc. Recent Development
Table 80. Merck KGaA Corporation Information
Table 81. Merck KGaA Description and Business Overview
Table 82. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Merck KGaA Metastatic Melanoma Drug Product
Table 84. Merck KGaA Recent Development
Table 85. Millennium Pharmaceuticals, Inc. Corporation Information
Table 86. Millennium Pharmaceuticals, Inc. Description and Business Overview
Table 87. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product
Table 89. Millennium Pharmaceuticals, Inc. Recent Development
Table 90. Morphotek, Inc. Corporation Information
Table 91. Morphotek, Inc. Description and Business Overview
Table 92. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Morphotek, Inc. Metastatic Melanoma Drug Product
Table 94. Morphotek, Inc. Recent Development
Table 95. NewLink Genetics Corporation Corporation Information
Table 96. NewLink Genetics Corporation Description and Business Overview
Table 97. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. NewLink Genetics Corporation Metastatic Melanoma Drug Product
Table 99. NewLink Genetics Corporation Recent Development
Table 100. Novartis AG Corporation Information
Table 101. Novartis AG Description and Business Overview
Table 102. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Novartis AG Metastatic Melanoma Drug Product
Table 104. Novartis AG Recent Development
Table 105. Omeros Corporation Corporation Information
Table 106. Omeros Corporation Description and Business Overview
Table 107. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Omeros Corporation Metastatic Melanoma Drug Product
Table 109. Omeros Corporation Recent Development
Table 110. Oncolytics Biotech Inc. Corporation Information
Table 111. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Oncolytics Biotech Inc. Description and Business Overview
Table 113. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product
Table 114. Oncolytics Biotech Inc. Recent Development
Table 115. OncoSec Medical Inc. Corporation Information
Table 116. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. OncoSec Medical Inc. Description and Business Overview
Table 118. OncoSec Medical Inc. Metastatic Melanoma Drug Product
Table 119. OncoSec Medical Inc. Recent Development
Table 120. Ono Pharmaceutical Co., Ltd. Corporation Information
Table 121. Ono Pharmaceutical Co., Ltd. Description and Business Overview
Table 122. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product
Table 124. Ono Pharmaceutical Co., Ltd. Recent Development
Table 125. Pfizer Inc. Corporation Information
Table 126. Pfizer Inc. Description and Business Overview
Table 127. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Pfizer Inc. Metastatic Melanoma Drug Product
Table 129. Pfizer Inc. Recent Development
Table 130. Pharmis Biofarmaceutica, Lda. Corporation Information
Table 131. Pharmis Biofarmaceutica, Lda. Description and Business Overview
Table 132. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product
Table 134. Pharmis Biofarmaceutica, Lda. Recent Development
Table 135. Philogen S.p.A. Corporation Information
Table 136. Philogen S.p.A. Description and Business Overview
Table 137. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Philogen S.p.A. Metastatic Melanoma Drug Product
Table 139. Philogen S.p.A. Recent Development
Table 140. Plexxikon Inc. Corporation Information
Table 141. Plexxikon Inc. Description and Business Overview
Table 142. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Plexxikon Inc. Metastatic Melanoma Drug Product
Table 144. Plexxikon Inc. Recent Development
Table 145. Production Base and Market Concentration Rate of Raw Material
Table 146. Key Suppliers of Raw Materials
Table 147. Metastatic Melanoma Drug Distributors List
Table 148. Metastatic Melanoma Drug Customers List
Table 149. Market Key Trends
Table 150. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 151. Key Challenges
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Melanoma Drug Product Picture
Figure 2. Global Metastatic Melanoma Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Metastatic Melanoma Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Others Examples
Figure 9. Global Metastatic Melanoma Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Metastatic Melanoma Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Metastatic Melanoma Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Metastatic Melanoma Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Metastatic Melanoma Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Metastatic Melanoma Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Metastatic Melanoma Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Metastatic Melanoma Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Metastatic Melanoma Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Metastatic Melanoma Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Metastatic Melanoma Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Metastatic Melanoma Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Metastatic Melanoma Drug Players Market Share by Revenue in Metastatic Melanoma Drug 2015 & 2019
Figure 27. Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Metastatic Melanoma Drug Revenue Share by Type (2015-2020)
Figure 29. Global Metastatic Melanoma Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Metastatic Melanoma Drug Revenue Share by Application (2015-2020)
Figure 31. Global Metastatic Melanoma Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 33. United States Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 34. Europe Metastatic Melanoma Drug Sales Market Share by Company in 2019
Figure 35. Europe Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 36. Europe Metastatic Melanoma Drug Sales Market Share by Application in 2019
Figure 37. China Metastatic Melanoma Drug Sales Market Share by Company in 2019
Figure 38. China Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 39. China Metastatic Melanoma Drug Sales Market Share by Application in 2019
Figure 40. Japan Metastatic Melanoma Drug Sales Market Share by Company in 2019
Figure 41. Japan Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 42. Japan Metastatic Melanoma Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Metastatic Melanoma Drug Sales Market Share by Application in 2019
Figure 46. India Metastatic Melanoma Drug Sales Market Share by Company in 2019
Figure 47. India Metastatic Melanoma Drug Sales Market Share by Type in 2019
Figure 48. India Metastatic Melanoma Drug Sales Market Share by Application in 2019
Figure 49. Merck & Co., Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Merck KGaA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Millennium Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Morphotek, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. NewLink Genetics Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Omeros Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Oncolytics Biotech Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. OncoSec Medical Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Ono Pharmaceutical Co., Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Pfizer Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Pharmis Biofarmaceutica, Lda. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Philogen S.p.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Plexxikon Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Key Raw Materials Price Trend
Figure 64. Manufacturing Cost Structure of Metastatic Melanoma Drug
Figure 65. Manufacturing Process Analysis of Metastatic Melanoma Drug
Figure 66. Metastatic Melanoma Drug Industrial Chain Analysis
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Figure 69. Porter's Five Forces Analysis
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed